Uterine Cancer (Endometrial Carcinoma) – A Complete Patient Guide
Overview
Endometrial carcinoma, commonly called **uterine cancer**, is a malignant growth that originates in the lining of the uterus (the endometrium). It is the most common gynecologic cancer in high‑income countries.
- Incidence: In the United States, ~66,000 new cases are diagnosed each year, representing ~7% of all cancers in women.[1] American Cancer Society, 2024
- Age & gender: >90% occur in women, with a median diagnosis age of 62 years. While rare before menopause, <5% are diagnosed in women under 40.
- Geography: Higher rates in North America, Europe, and Australia; lower in Asia and Africa, partly reflecting obesity prevalence.
Symptoms
Early detection hinges on recognizing the often subtle signs. Not all women experience every symptom, and some may have none until the disease is advanced.
Most common presenting symptom
- Abnormal uterine bleeding:
- Post‑menopausal bleeding (any spotting after 12 months of amenorrhea) – the single most alarming sign.
- Heavy, prolonged, or irregular menstrual bleeding in pre‑menopausal women.
Other possible symptoms
- Pelvic pain or pressure: May be dull or cramp‑like, sometimes radiating to the lower back.
- Vaginal discharge: Often watery or pink‑tinged.
- Feeling of fullness in the pelvis: Can be due to a growing tumor.
- Unexplained weight loss or fatigue: More common in advanced disease.
- Symptoms of metastasis: Persistent cough, bone pain, or abdominal swelling (ascites) when cancer spreads.
Causes and Risk Factors
The exact cause is unknown, but most cases are linked to hormonal imbalances—particularly excess estrogen without counterbalancing progesterone.
Key risk factors
- Age: Risk rises sharply after menopause.
- Obesity: Women with BMI ≥30 have a 2–4‑fold higher risk; adipose tissue converts androstenedione to estrogen.[2] WHO, 2023
- Hormonal factors:
- Early menarche (<12 years) or late menopause (>55 years).
- Never having been pregnant (nulliparity) or infertility.
- Unopposed estrogen therapy (estrogen‑only HRT) or estrogen‑producing ovarian tumors.
- Diabetes & insulin resistance: Hyperinsulinemia may stimulate endometrial growth.
- Polycystic ovary syndrome (PCOS): Chronic anovulation leads to prolonged estrogen exposure.
- Family history & genetics:
- Lynch syndrome (hereditary non‑polyposis colorectal cancer) – 40‑60% risk of endometrial cancer.
- BRCA1/2 mutations (especially BRCA1) modestly increase risk.
- Previous radiation therapy: Pelvic radiation for other cancers raises risk.
- Tamoxifen use: A selective estrogen receptor modulator used for breast cancer can act as an estrogen agonist in the uterus.
Diagnosis
When a clinician suspects endometrial cancer, a systematic approach is used to confirm the diagnosis, stage the tumor, and guide treatment.
1. Clinical evaluation
- Detailed medical history (bleeding pattern, risk factors, family history).
- Physical examination, including bimanual pelvic exam.
2. Imaging & laboratory tests
- Transvaginal ultrasound (TVUS): First‑line imaging; endometrial thickness >4 mm in post‑menopausal women is considered abnormal.
- Pelvic MRI: Best for local staging (depth of myometrial invasion, cervical involvement).
- CT scan or PET‑CT: Used when metastasis is suspected.
- Blood tests: Complete blood count, renal & liver function; CA‑125 may be elevated but is not diagnostic.
3. Tissue sampling
- Endometrial biopsy: Office‑based pipelle or dilation & curettage (D&C) provides histology.
- Hysteroscopic-guided biopsy: Direct visualization and targeted sampling for focal lesions.
- Pathology reports classify tumors by type (endometrioid, serous, clear cell, carcinosarcoma) and grade (1‑3).
4. Staging (AJCC 8th edition)
- Stage I – confined to uterus.
- Stage II – invades cervical stroma.
- Stage III – local spread to uterus, adnexa, or pelvic nodes.
- Stage IV – bladder/rectal mucosa or distant metastasis.
Treatment Options
Treatment is individualized based on stage, histology, patient age, comorbidities, and fertility desires.
Surgical Management (standard for most stages)
- Total hysterectomy with removal of both fallopian tubes and ovaries (bilateral salpingo‑oophorectomy).
- Pelvic and para‑aortic lymph node assessment: Sentinel‑node biopsy or systematic lymphadenectomy.
- For early‑stage, low‑grade disease, ovarian preservation may be considered in young women desiring fertility.
Radiation Therapy
- External beam radiation therapy (EBRT): Reduces local recurrence, often used after surgery for high‑risk features.
- Vaginal brachytherapy: Delivers radiation directly to the vaginal cuff; lower side‑effects than EBRT.
- Combined modality (EBRT + brachy) for stage III or high‑risk stage I/II.
Systemic Therapy
- Hormonal therapy: Progestins (medroxyprogesterone acetate, megestrol) for low‑grade, estrogen‑receptor‑positive tumors, especially in women who cannot undergo surgery.
- Chemotherapy:
- Carboplatin + paclitaxel is the most common regimen for advanced or high‑grade disease.
- For recurrent disease, regimens may include doxorubicin, ifosfamide, or newer agents (e.g., pembrolizumab for MSI‑high tumors).
- Targeted/Immunotherapy:
- PD‑1 inhibitors (pembrolizumab, dostarlimab) approved for microsatellite instability‑high (MSI‑H) or mismatch repair‑deficient (dMMR) tumors.
- Trastuzumab for HER2‑positive serous carcinoma.
Lifestyle & Supportive Measures
- Weight management and regular exercise to improve outcomes.
- Smoking cessation (if applicable).
- Pain control, anti‑nausea meds, and psychosocial counseling.
Living with Uterine Cancer (Endometrial Carcinoma)
Diagnosis can be overwhelming, but many women lead active lives during and after treatment.
Physical well‑being
- Post‑surgical care: Follow incision care instructions; avoid heavy lifting >10 lbs for 4‑6 weeks.
- Managing side effects:
- Radiation may cause vaginal dryness—use water‑based lubricants.
- Chemotherapy can cause fatigue; schedule rest periods and gentle activity.
- Nutrition: Emphasize lean protein, whole grains, fruits, and vegetables; limit processed sugars to help weight control.
Emotional & mental health
- Join support groups (local hospital, CancerCare, online forums).
- Consider counseling or cognitive‑behavioral therapy for anxiety/depression.
- Mind‑body practices—yoga, meditation, or tai chi—have shown benefits for cancer‑related fatigue.
Follow‑up schedule
- First post‑treatment visit 4‑6 weeks after surgery or radiation.
- Every 3–6 months for the first 2 years, then annually up to 5 years.
- Routine pelvic exam, symptom review, and imaging only if indicated.
Fertility considerations
- Younger women with early-stage disease may be candidates for fertility‑sparing treatment (high‑dose progestin therapy combined with hysteroscopic monitoring).
- Consult a reproductive endocrinologist about embryo or egg freezing before definitive surgery.
Prevention
While not all cases are preventable, several modifiable factors markedly lower risk.
- Maintain a healthy weight: Aim for BMI 18.5–24.9; even a 5‑% weight loss can reduce estrogen production.
- Physical activity: ≥150 minutes of moderate aerobic exercise per week.
- Balanced hormone use: If menopausal hormone therapy is needed, choose combined estrogen‑plus‑progestin regimens and use the lowest effective dose for the shortest duration.
- Manage diabetes & insulin resistance: Diet, exercise, and medications as prescribed.
- Screen high‑risk individuals:
- Lynch syndrome carriers should undergo annual endometrial sampling starting at age 30 or consider prophylactic hysterectomy after childbearing.
- Women on long‑term tamoxifen should have periodic pelvic examinations.
Complications
If left untreated or if disease recurs, serious complications can arise.
- Local spread: Invasion into the myometrium, cervix, bladder, or rectum causing urinary or bowel obstruction.
- Vaginal fistulas: Abnormal connections leading to continuous discharge.
- Metastatic disease: Lungs, liver, bone, or brain involvement.
- Deep vein thrombosis (DVT) / pulmonary embolism: Higher risk after major surgery or chemotherapy.
- Secondary infertility: Resulting from hysterectomy or radiation.
- Psychosocial impact: Depression, anxiety, and body‑image concerns.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Severe, sudden pelvic or abdominal pain with swelling.
- Heavy vaginal bleeding soaking through a pad every hour.
- Fever >38 °C (100.4 °F) with chills, especially after surgery.
- Shortness of breath, chest pain, or sudden cough (possible blood clot or lung involvement).
- Sudden weakness, numbness, or difficulty speaking (rare sign of brain metastasis).
References
- American Cancer Society. Uterine (Endometrial) Cancer—2024 Statistics.
- World Health Organization. Obesity and Cancer Fact Sheet. 2023.
- Mayo Clinic. Endometrial (Uterine) Cancer – Symptoms and Causes.
- Cleveland Clinic. Uterine Cancer: Diagnosis and Staging.
- National Comprehensive Cancer Network (NCCN). Uterine Neoplasms Guidelines, Version 2.2024.
- National Institutes of Health. PD‑1 Inhibitors in MSI‑H Endometrial Cancer. 2022.